Cargando…

Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study

BACKGROUND: Lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of cancer that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC). The population-based analysis of LELC and the optimal treatment remains unclear. MATERIALS AND METHODS: This real-world, retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Meiting, Chen, Yungchang, Fang, Xiaojie, Wang, Zhao, Pu, Xingxiang, Liang, Chaoyong, Guo, Hongqiang, Li, Qian, Pan, Fei, Hong, Huangming, Huang, He, Li, Jiman, Lin, Tongyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494884/
https://www.ncbi.nlm.nih.gov/pubmed/36138362
http://dx.doi.org/10.1186/s12890-022-02097-6
_version_ 1784793889363722240
author Chen, Meiting
Chen, Yungchang
Fang, Xiaojie
Wang, Zhao
Pu, Xingxiang
Liang, Chaoyong
Guo, Hongqiang
Li, Qian
Pan, Fei
Hong, Huangming
Huang, He
Li, Jiman
Lin, Tongyu
author_facet Chen, Meiting
Chen, Yungchang
Fang, Xiaojie
Wang, Zhao
Pu, Xingxiang
Liang, Chaoyong
Guo, Hongqiang
Li, Qian
Pan, Fei
Hong, Huangming
Huang, He
Li, Jiman
Lin, Tongyu
author_sort Chen, Meiting
collection PubMed
description BACKGROUND: Lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of cancer that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC). The population-based analysis of LELC and the optimal treatment remains unclear. MATERIALS AND METHODS: This real-world, retrospective study investigated 770 patients with LELC for primary site, treatment, and survival outcomes from 2005 to 2019 from five cancer centres in China. The overall survival (OS) of different subgroups was appraised by log-rank tests and Kaplan–Meier analysis. RESULTS: Primary sites LELC included the lung (597 cases, 77.5%), salivary gland (115 cases, 14.9%), and others. The median progression-free survival (PFS) of LELC patients was 47.4 months. The median overall survival (OS) was not reached. The 5-year survival rate for LELC patients was 77.8%. Most patients in stages I and II received surgery. The majority of patients in stage III received surgery and radiotherapy. More than half of the patients in stage IV received chemotherapy. Among relapsed or metastatic cases receiving chemotherapy, patients who received immunotherapy at any time presented with a superior OS than those without immunotherapy (P < 0.0001, HR = 0.39, 95% CI 0.25–0.63). Compared with the SEER database, patients with LELC had a better prognosis than NPC, with a 5-year overall survival of 77.3% vs. 56.8% (P < 0.001). CONCLUSION: Our data provide treatment patterns and outcomes for LELC from various primary sites. Randomized controlled studies are necessary to further define the standard of care for patients with LELC. Trial registration This clinical trial was registered at ClinicalTrials.gov (No. NCT04614818). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02097-6.
format Online
Article
Text
id pubmed-9494884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94948842022-09-23 Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study Chen, Meiting Chen, Yungchang Fang, Xiaojie Wang, Zhao Pu, Xingxiang Liang, Chaoyong Guo, Hongqiang Li, Qian Pan, Fei Hong, Huangming Huang, He Li, Jiman Lin, Tongyu BMC Pulm Med Research BACKGROUND: Lymphoepithelioma-like carcinoma (LELC) is a rare and unique subtype of cancer that histologically resembles undifferentiated nasopharyngeal carcinoma (NPC). The population-based analysis of LELC and the optimal treatment remains unclear. MATERIALS AND METHODS: This real-world, retrospective study investigated 770 patients with LELC for primary site, treatment, and survival outcomes from 2005 to 2019 from five cancer centres in China. The overall survival (OS) of different subgroups was appraised by log-rank tests and Kaplan–Meier analysis. RESULTS: Primary sites LELC included the lung (597 cases, 77.5%), salivary gland (115 cases, 14.9%), and others. The median progression-free survival (PFS) of LELC patients was 47.4 months. The median overall survival (OS) was not reached. The 5-year survival rate for LELC patients was 77.8%. Most patients in stages I and II received surgery. The majority of patients in stage III received surgery and radiotherapy. More than half of the patients in stage IV received chemotherapy. Among relapsed or metastatic cases receiving chemotherapy, patients who received immunotherapy at any time presented with a superior OS than those without immunotherapy (P < 0.0001, HR = 0.39, 95% CI 0.25–0.63). Compared with the SEER database, patients with LELC had a better prognosis than NPC, with a 5-year overall survival of 77.3% vs. 56.8% (P < 0.001). CONCLUSION: Our data provide treatment patterns and outcomes for LELC from various primary sites. Randomized controlled studies are necessary to further define the standard of care for patients with LELC. Trial registration This clinical trial was registered at ClinicalTrials.gov (No. NCT04614818). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-022-02097-6. BioMed Central 2022-09-22 /pmc/articles/PMC9494884/ /pubmed/36138362 http://dx.doi.org/10.1186/s12890-022-02097-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Meiting
Chen, Yungchang
Fang, Xiaojie
Wang, Zhao
Pu, Xingxiang
Liang, Chaoyong
Guo, Hongqiang
Li, Qian
Pan, Fei
Hong, Huangming
Huang, He
Li, Jiman
Lin, Tongyu
Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
title Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
title_full Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
title_fullStr Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
title_full_unstemmed Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
title_short Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
title_sort clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494884/
https://www.ncbi.nlm.nih.gov/pubmed/36138362
http://dx.doi.org/10.1186/s12890-022-02097-6
work_keys_str_mv AT chenmeiting clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT chenyungchang clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT fangxiaojie clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT wangzhao clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT puxingxiang clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT liangchaoyong clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT guohongqiang clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT liqian clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT panfei clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT honghuangming clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT huanghe clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT lijiman clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy
AT lintongyu clinicalfeaturesandtreatmentoutcomeoflymphoepitheliomalikecarcinomafrommultipleprimarysitesapopulationbasedmulticentrerealworldstudy